This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Special considerations arising from the use of psychotropic drugs during early pregnancy

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Seek specialist advice.

  • if a pregnant woman was taking drugs with known teratogenic risk (lithium, valproate, carbamazepine, lamotrigine and paroxetine) at the time of conception and/or in the first trimester, healthcare professionals should:
    • confirm the pregnancy as quickly as possible · offer appropriate screening and counselling about the continuation of the pregnancy, the need for additional monitoring and the risks to the fetus if the woman continues to take medication
    • undertake a full paediatric assessment of the newborn infant
    • monitor the infant in the first few weeks after delivery for adverse drug effects, drug toxicity or withdrawal (for example, floppy baby syndrome, irritability, constant crying, shivering, tremor, restlessness, increased tone, feeding and sleeping difficulties and, rarely, seizures); if the mother was prescribed antidepressants in the last trimester, these may result from serotonergic toxicity syndrome rather than withdrawal
    • infants of mothers who are breastfeeding while taking psychotropic medication should be monitored for adverse reactions

Reference:

  1. NICE (2007). Antenatal and postnatal mental health

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.